Host |
Rabbit |
Klon |
SP117 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Heart |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from C-terminus of human vinculin protein |
Lokalisation |
Membrane and cytoplasm |
Vinculin
|
Zytomed Systems GmbH |
SP117 |
0.5 ml |
Concentrate |
RUO |
522-4172 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Purified |
Methode |
EL, IF |
Isotyp |
Rabbit IgG |
Verdünnung |
Amino acids 501-511 of vesicular stomatitis virus glycoprotein (VSV-G) |
VSV, G Protein (Epitope Tag) (Vesicular Stomatitis Virus)
|
Zytomed Systems GmbH |
polyclonal |
50 µg |
Purified |
RUO |
622-0075 |
-
|
Host |
Mouse |
Klon |
6F-H2 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Malignant mesothelioma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Purified WT protein |
Lokalisation |
Nucleus |
WT-1
|
Zeta Corporation |
6F-H2 |
1ml |
Concentrate |
CE/IVD |
Z2124ML |
-
|
Host |
Mouse |
Klon |
6F-H2 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Malignant mesothelioma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Purified WT protein |
Lokalisation |
Nucleus |
WT-1
|
Zeta Corporation |
6F-H2 |
7 ml |
Ready-to-use |
CE/IVD |
Z2124MP |
-
|
Host |
Mouse |
Klon |
6F-H2 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Malignant mesothelioma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Purified WT protein |
Lokalisation |
Nucleus |
WT-1
|
Zeta Corporation |
6F-H2 |
0.5 ml |
Concentrate |
CE/IVD |
Z2124MS |
-
|
Host |
Mouse |
Klon |
6F-H2 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Malignant mesothelioma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Purified WT protein |
Lokalisation |
Nucleus |
WT-1
|
Zeta Corporation |
6F-H2 |
0.1 ml |
Concentrate |
CE/IVD |
Z2124MT |
-
|
Host |
Mouse |
Klon |
6F-H2 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Wilm's Tumor |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm, nucleus |
WT1 (Wilm's Tumor Protein-1)
|
Diagnostic Biosystems |
6F-H2 |
1 ml |
Concentrate |
CE/IVD |
MOB437 |
-
|
Host |
Mouse |
Klon |
6F-H2 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Wilm's Tumor |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm, nucleus |
WT1 (Wilm's Tumor Protein-1)
|
Diagnostic Biosystems |
6F-H2 |
0.1 ml |
Concentrate |
CE/IVD |
MOB437-01 |
-
|
Host |
Mouse |
Klon |
6F-H2 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Wilm's Tumor |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm, nucleus |
WT1 (Wilm's Tumor Protein-1)
|
Diagnostic Biosystems |
6F-H2 |
0.5 ml |
Concentrate |
CE/IVD |
MOB437-05 |
-
|
Host |
Mouse |
Klon |
6F-H2 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Wilm´s tumor |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm, nucleus |
WT1 (Wilm's Tumor Protein-1)
|
Zytomed Systems GmbH |
6F-H2 |
6 ml |
Ready-to-use |
RUO |
MSG124 |
-
|
Host |
Mouse |
Klon |
6F-H2 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Wilm's Tumor |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm, nucleus |
WT1 (Wilm's Tumor Protein-1)
|
Zytomed Systems GmbH |
6F-H2 |
0.5 ml |
Concentrate |
RUO |
MSK124-05 |
-
|
Host |
Mouse |
Klon |
6F-H2 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Wilm´s tumor |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm, nucleus |
WT1 (Wilm's Tumor Protein-1)
|
Diagnostic Biosystems |
6F-H2 |
6 ml |
Ready-to-use |
CE/IVD |
PDM177 |
-
|
Host |
Mouse |
Klon |
6F-H2 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Wilm´s tumor |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm, nucleus |
WT1 (Wilm's Tumor Protein-1)
|
Diagnostic Biosystems |
6F-H2 |
25 ml |
Ready-to-use |
CE/IVD |
PDM177-25 |
-
|
Host |
Mouse |
Klon |
rWT1/857 |
Format |
concentrate |
Methode |
P |
Vorbehandlung |
Citrate o EDTA |
Positivkontrolle |
Wilms' tumor, mesothelioma, or normal kidney |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant full-length human WT1 protein |
Lokalisation |
Nuclear and cytoplasmic |
WT1 [rWT1/857]
|
Biocare Medical |
rWT1/857 |
0.1 ml |
concentrate |
CE/IVD |
ACI3238A |
-
|
Host |
Mouse |
Klon |
rWT1/857 |
Format |
concentrate |
Methode |
P |
Vorbehandlung |
Citrate o EDTA |
Positivkontrolle |
Wilms' tumor, mesothelioma, or normal kidney |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant full-length human WT1 protein |
Lokalisation |
Nuclear and cytoplasmic |
WT1 [rWT1/857]
|
Biocare Medical |
rWT1/857 |
1ml |
concentrate |
CE/IVD |
ACI3238C |
-
|
Host |
Mouse |
Klon |
rWT1/857 |
Format |
ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate o EDTA |
Positivkontrolle |
Wilms' tumor, mesothelioma, or normal kidney |
Verdünnung |
--- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant full-length human WT1 protein |
Lokalisation |
Nuclear and cytoplasmic |
WT1 [rWT1/857]
|
Biocare Medical |
rWT1/857 |
6ml |
ready-to-use |
CE/IVD |
API3238AA |
-
|
Host |
Mouse |
Klon |
33-2-5 |
Format |
Concentrate |
Methode |
F, P, WB, IP, IF |
Vorbehandlung |
Citrate |
Positivkontrolle |
Testis |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG2b |
Lokalisation |
Nucleus |
XRCC1
|
Diagnostic Biosystems |
33-2-5 |
1 ml |
Concentrate |
RUO |
MOB325 |
-
|
Host |
Mouse |
Klon |
33-2-5 |
Format |
Concentrate |
Methode |
F, P, WB, IP, IF |
Vorbehandlung |
Citrate |
Positivkontrolle |
Testis |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG2b |
Lokalisation |
Nucleus |
XRCC1
|
Diagnostic Biosystems |
33-2-5 |
0.1 ml |
Concentrate |
RUO |
MOB325-01 |
-
|
Host |
Mouse |
Klon |
33-2-5 |
Format |
Concentrate |
Methode |
F, P, WB, IP, IF |
Vorbehandlung |
Citrate |
Positivkontrolle |
Testis |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG2b |
Lokalisation |
Nucleus |
XRCC1
|
Diagnostic Biosystems |
33-2-5 |
0.5 ml |
Concentrate |
RUO |
MOB325-05 |
-
|
Host |
Monospecific Mouse |
Klon |
ZM97 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil, CLL/SLL. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment of human ZAP70 protein (around aa247-382) |
Lokalisation |
Cytoplasm |
ZAP-70
|
Zeta Corporation |
ZM97 |
1 ml |
Concentrate |
CE/IVD |
Z2407ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM97 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil, CLL/SLL. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment of human ZAP70 protein (around aa247-382) |
Lokalisation |
Cytoplasm |
ZAP-70
|
Zeta Corporation |
ZM97 |
7 ml |
Ready-to-use |
CE/IVD |
Z2407MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM97 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil, CLL/SLL. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment of human ZAP70 protein (around aa247-382) |
Lokalisation |
Cytoplasm |
ZAP-70
|
Zeta Corporation |
ZM97 |
0.5 ml |
Concentrate |
CE/IVD |
Z2407MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM97 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil, CLL/SLL. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment of human ZAP70 protein (around aa247-382) |
Lokalisation |
Cytoplasm |
ZAP-70
|
Zeta Corporation |
ZM97 |
0.1 ml |
Concentrate |
CE/IVD |
Z2407MT |
-
|